Atara Biotherapeutics (ATRA) vs Equillium (EQ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Equillium (EQ) has outperformed Atara Biotherapeutics (ATRA) over the past year, losing 2.0% versus a loss of 41.8%. Over five years, EQ leads with a -75.6% price change compared with -97.6% for ATRA. Atara Biotherapeutics is the larger company by market cap ($92.6 million vs $91.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATRA | EQ |
|---|---|---|
| Share price | $9.23 | $1.44 |
| Market cap | $92.65M | $91.31M |
| 1-day change | -1.49% | +3.60% |
| YTD return | -48.98% | -7.10% |
| 1-year return | -41.77% | -2.04% |
| 5-year return | -97.56% | -75.63% |
| Forward P/E | 5.97 | — |
| EPS (TTM) | $-1.26 | $-0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.15 | $3.54 |
| 52-week low | $3.92 | $0.76 |
| Distance from 52-week high | -51.79% | -59.32% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +48.10% | +494.44% |
| Average volume | 53.79K | 583.72K |
| Shares outstanding | 10.04M | 63.41M |
| Employees | 10 | 14 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EQ has outperformed ATRA by 39.7 percentage points over the past year.
About Atara Biotherapeutics
ATRA stock →Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally.
Healthcare · Biotechnology · 10 employees
About Equillium
EQ stock →Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases.
Healthcare · Biotechnology · 14 employees
ATRA vs EQ FAQ
Which is bigger, Atara Biotherapeutics or Equillium?
Atara Biotherapeutics (ATRA) is larger, with a market capitalization of $92.65M compared with $91.31M for Equillium (EQ).
Which stock has performed better over the past year, ATRA or EQ?
EQ returned -2.04% over the past 12 months, compared with -41.77% for ATRA (price return, excluding dividends). Past performance does not predict future results.
Are Atara Biotherapeutics and Equillium in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.